U.S. Markets open in 6 hrs 38 mins

PowerShares Dynamic Retail ETF (PMR)


NYSEArca - Nasdaq Real Time Price. Currency in USD
Add to watchlist
36.31+0.42 (+1.18%)
At close: 3:42PM EDT
People also watch
PEJPSJPBSPICPUI
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close35.88
Open36.27
Bid0.00 x
Ask0.00 x
Day's Range36.27 - 36.31
52 Week Range33.52 - 38.86
Volume380
Avg. Volume3,632
Net Assets13.99M
NAV34.97
PE Ratio (TTM)N/A
Yield0.92%
YTD Return-2.38%
Beta (3y)0.56
Expense Ratio (net)0.63%
Inception Date2005-10-26
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    PharmaMar Demonstrates Its Progress in R&D in New York

    Under the title of "R&D Day", PharmaMar (PHM) hosted an investor meeting in New York to demonstrate its evolution and potential in the areas of R&D. Various members of PharmaMar's management team, together with key global opinion leaders in oncology discussed the company's scientific pipeline. With the aim of defining and contextualizing PharmaMar's research work, the meeting saw the participation of Dr Melinda Telli, an oncologist from the School of Medicine of the University of Stanford, and Dr Martin Forster, an oncologist from the University College of London. Both experts explained their investigative experience and the progress and positive results that have been obtained up to now with lurbinectedin (PM1183), the most advanced molecule in the PharmaMar pipeline, a transcription inhibitor which is directed at treating various cancer including hereditary breast cancer (discussed by Dr Telli) and small cell lung cancer (discussed by Dr Forster) respectively.

  • PR Newswire7 days ago

    PharmaMar to Host Research and Development Event today in New York

    MADRID, April 24, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM), a leading biopharmaceutical company focused on the discovery and development of innovative marine-derived anticancer drugs, will host today ...

  • PR Newswire25 days ago

    PharmaMar to Host Research and Development Event on April 24, 2017

    MADRID, April 6, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM), a leading biopharmaceutical company focused on the discovery and development of innovative marine-derived anticancer drugs, today announced that ...